Skip to main content
An Extremely Indolent T-cell Leukemia: An 18-year Follow-Up.
J Community Support Oncol
  • Samuel Adediran, MD, Lehigh Valley Health Network
  • Dennis B Cornfield, MD, Lehigh Valley Health Network
  • Adam Bagg, University of Pennsylvania Medical Center, Philadelphia, PA
  • Nicole M Agostino, DO, Lehigh Valley Health Network
Publication/Presentation Date
T-cell prolymphocytic leukemia (T-PLL) is a rare malignancy that comprises about 2% of all mature lymphoid neoplasms. Patients usually present with prominent peripheral blood lymphocytosis, splenomegaly, hepatomegaly, lymphadenopathy, B symptoms, and occasionally with skin lesions.¹ The disease follows an aggressive clinical course with rapid progression and typically has a median survival of less than 1 year. In some cases, the disease is indolent for a period of time before becoming aggressive.² In 2002, 7 years after initial diagnosis in 1995, the case discussed herein was reported as a rare, indolent form of T-PLL.³ We now present 11 additional years of follow-up of this case, during which time the patient remained asymptomatic with respect to his lymphoid neoplasm.
Document Type
Citation Information

Adediran, S., Cornfield, D., Bagg, A., & Agostino, N. (2016). An extremely indolent T-cell leukemia: an 18-year follow-up. The Journal Of Community And Supportive Oncology, 14(2), 76-78. doi:10.12788/jcso.0190.